RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. (http://www.talecris.com) announced today that as of October 1, 2007, all new releases of its line of HypermunesTM (hyperimmune globulin therapies) are latex-free. With the elimination of latex from the vial rubber stoppers and prefilled syringes, physicians can confidently use Talecris’ Hypermunes in their patients with latex allergy. This latest action represents the ongoing Talecris effort to support “latex-free” medical environments.
